Humabodies are based on fully human single antibody VH domains that offer a unique combination of potential benefits compared with conventional monoclonal antibodies. They are the smallest possible immunoglobulin-based binding domain and biophysically highly robust, enabling Crescendo to create bespoke medicines including mono- and multi-functional therapeutics. Humabodies can penetrate tissues including solid tumours and accumulate much more effectively than conventional antibodies or antibody fragments such as Fab fragments which are four times larger than a VH Humabody® . Manufacture is simple and cost effective and they can be formulated for a variety of different routes of administration. As such, we can create unique medicines capable of novel target engagement and enhanced therapeutic index for optimal cancer killing.